文献速递免疫规划

新冠疫情前后北半球季节性流感疫苗效果的系统荟萃分析

A systematic meta-analytic comparative evaluation of seasonal influenza vaccine effectiveness from test-negative design studies in the Northern Hemisphere pre/post COVID-19 pandemic.
PubMed 文献 · Vaccine · 2026-07-22

该系统综述纳入85篇检测阴性设计研究,比较新冠疫情前后北半球季节性流感疫苗效果。结果显示,6月龄至17岁和18-64岁人群疫情后A(H3N2)和B型流感疫苗效果显著高于疫情前,但18-64岁人群疫情后A(H1N1)pdm09疫苗效果较低;≥65岁人群无显著差异,B/Victoria数据有限。

要点

  • 疫情后6月龄至17岁人群A(H3N2)疫苗效果为53%,高于疫情前37%。
  • 疫情后18-64岁人群A(H3N2)疫苗效果为35%,高于疫情前21%。
  • 疫情后18-64岁人群A(H1N1)pdm09疫苗效果为37%,低于疫情前55%。

核心结论

  • 证据提示新冠疫情后季节性流感疫苗效果略高,但可能存在人群免疫以外的因素解释该观察。

研究设计与样本

  • 系统综述与荟萃分析,纳入85篇检测阴性设计研究,比较北半球疫情前(2010/11-2019/20)与疫情后(2022/23-2024/25)的疫苗效果。

主要发现

  • 疫情后6月龄至17岁人群A(H3N2)疫苗效果为53%(42-64%),高于疫情前37%(30-45%)。
  • 疫情后18-64岁人群A(H3N2)疫苗效果为35%(25-45%),高于疫情前21%(13-29%)。
  • 疫情后6月龄至17岁人群B型流感疫苗效果为85%(78-93%),高于疫情前52%(45-60%)。
  • 疫情后18-64岁人群B型流感疫苗效果为73%(59-87%),高于疫情前49%(41-57%)。
  • 疫情后18-64岁人群A(H1N1)pdm09疫苗效果为37%(27-46%),低于疫情前55%(47-62%)。

临床怎么用

  • 在6月龄至17岁和18-64岁人群中,疫情后流感疫苗接种对A(H3N2)和B型流感的保护效果可能有所提高。
  • 对18-64岁人群,疫情后A(H1N1)pdm09疫苗效果可能低于疫情前,需关注该亚型的免疫策略。

局限性

  • ≥65岁人群未观察到显著差异,B/Victoria数据有限。
  • 观察到的疫苗效果变化可能受人群免疫以外的因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza circulation was substantially reduced during the COVID-19 pandemic. The consequent reduction in population immunity may have resulted in increased influenza vaccine effectiveness (VE) after the pandemic via reduced immunity in unvaccinated individuals compared to the pre-pandemic period. METHODS: We systematically reviewed published peer-reviewed test-negative design (TND) studies of seasonal influenza VE against medically-attended, laboratory-confirmed influenza in the Northern Hemisphere. We compared pooled VE estimates before (2010/11-2019/20) and after (2022/23-2024/25) the COVID-19 pandemic (defined as 2020/21-2021/22). Pooled VE against A(H1N1)pdm09, A(H3N2), influenza B, and B/Victoria was calculated for three age groups (6 months-17 years, 18-64 years, ≥65 years) using inverse-variance random-effects meta-analysis. Heterogeneity was quantified with the I2 statistic, and differences between pooled VE estimates pre- and post-pandemic periods were tested with the χ2 statistic. RESULTS: Eighty-five publications were included. Post-pandemic VE against A(H3N2) was significantly higher than pre-pandemic VE in 6-month-17-year-olds (53% [42-64%] vs 37% [30-45%]) and 18-64-year-olds (35% [25-45%] vs 21% [13-29%]). Similarly, VE against influenza B was higher post-pandemic in both age groups (85% [78-93%] vs 52% [45-60%] and 73% [59-87%] vs 49% [41-57%], respectively). Conversely, VE against A(H1N1)pdm09 was lower post-pandemic in 18-64-year-olds (37% [27-46%] vs 55% [47-62%]). No significant differences were observed for ≥65-year-olds, and data for B/Victoria were limited. CONCLUSIONS: The evidence suggests slightly higher VE against seasonal influenza after the COVID-19 pandemic although there may be factors other than population immunity that may explain our observations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Okoli GN, Sullivan SG, Harper DM, et al. A systematic meta-analytic comparative evaluation of seasonal influenza vaccine effectiveness from test-negative design studies in the Northern Hemisphere pre/post COVID-19 pandemic. Vaccine. 2026. PMID: 42486051. doi:10.1016/j.vaccine.2026.128956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。